Diagnosing and Treating ICU-Acquired Pneumonia in the Era of MDR Pathogens: Rapid Diagnostics and New Antibiotics

Dr Neeraj Manikath , claude.ai

Abstract

Background: ICU-acquired pneumonia, encompassing ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP), remains a leading cause of morbidity and mortality in critically ill patients. The emergence of multidrug-resistant (MDR) pathogens has fundamentally transformed the diagnostic and therapeutic landscape, necessitating rapid diagnostic approaches and novel antimicrobial strategies.

Objective: To provide a comprehensive review of contemporary diagnostic methodologies and therapeutic approaches for ICU-acquired pneumonia in the context of increasing antimicrobial resistance.

Methods: We reviewed recent literature on rapid diagnostic techniques, antimicrobial stewardship principles, and novel antibiotics approved for MDR pathogens causing ICU-acquired pneumonia.

Results: Rapid molecular diagnostics, including multiplex PCR and MALDI-TOF MS, have revolutionized pathogen identification and resistance detection. New antibiotics such as ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol offer therapeutic options against previously untreatable MDR organisms.

Conclusions: Early recognition, rapid diagnostics, and judicious use of new antibiotics, combined with robust antimicrobial stewardship, are essential for optimizing outcomes in ICU-acquired pneumonia caused by MDR pathogens.

Keywords: ICU-acquired pneumonia, multidrug resistance, rapid diagnostics, novel antibiotics, antimicrobial stewardship

Introduction

ICU-acquired pneumonia represents one of the most challenging infectious complications in critical care medicine, affecting 10-15% of mechanically ventilated patients and carrying mortality rates of 20-50%.¹ The landscape has been dramatically altered by the proliferation of multidrug-resistant (MDR) pathogens, including carbapenem-resistant Enterobacterales (CRE), methicillin-resistant Staphylococcus aureus (MRSA), and extensively drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.²

The traditional approach of empirical broad-spectrum therapy followed by culture-guided de-escalation has proven inadequate in the MDR era, where delayed appropriate therapy significantly increases mortality.³ This paradigm shift necessitates rapid diagnostic capabilities and access to novel antimicrobial agents specifically designed to combat resistant organisms.

This review synthesizes current evidence on diagnostic innovations and therapeutic advances, providing practical guidance for intensivists managing ICU-acquired pneumonia in the contemporary era of antimicrobial resistance.

Epidemiology and Risk Factors

Changing Pathogen Landscape

The microbiology of ICU-acquired pneumonia has evolved significantly over the past decade. While traditional pathogens such as S. aureus, Streptococcus pneumoniae, and Haemophilus influenzae remain important, gram-negative MDR organisms now predominate in many ICUs.⁴

Key Epidemiological Trends:

CRE infections increased by 75% in ICUs between 2015-2020⁵
MDR P. aeruginosa prevalence ranges from 15-35% globally⁶
Carbapenem-resistant A. baumannii (CRAB) accounts for >80% of Acinetobacter isolates in some regions⁷

Risk Stratification for MDR Pathogens

🔍 Clinical Pearl: Use the following risk stratification framework for empirical therapy selection:

High Risk for MDR Pathogens:

Prior antimicrobial therapy within 90 days
Hospitalization ≥5 days
High local MDR prevalence (>10-20%)
Immunosuppression
Structural lung disease
Previous MDR isolation

🦪 Oyster Alert: Beware of the "healthy" patient with acute respiratory failure—community-acquired MDR pneumonia is increasingly recognized, particularly with hypervirulent Klebsiella pneumoniae.⁸

Diagnostic Approaches

Clinical Diagnosis Challenges

Clinical diagnosis of ICU-acquired pneumonia remains problematic due to non-specific symptoms and signs in critically ill patients. The classical triad of fever, purulent sputum, and new infiltrates occurs in <50% of cases.⁹

💡 Clinical Hack: Implement the modified Clinical Pulmonary Infection Score (CPIS) with biomarker enhancement:

Traditional CPIS + procalcitonin >0.5 ng/mL increases diagnostic accuracy to 78%¹⁰
Serial C-reactive protein measurements help differentiate bacterial from viral pneumonia

Rapid Molecular Diagnostics

Multiplex PCR Platforms

Modern molecular diagnostics have transformed pathogen identification timeframes from days to hours.

FilmArray Pneumonia Panel:

Identifies 33 pathogens and resistance markers in 1 hour
Sensitivity: 90-95% for bacterial pathogens¹¹
Limitations: Cannot quantify organisms, expensive per test

BioFire RP2.1 Panel:

Respiratory pathogen panel with antimicrobial resistance genes
Turnaround time: 45 minutes
Particularly useful for mecA (MRSA) and vanA/vanB (VRE) detection¹²

🔍 Clinical Pearl: Negative multiplex PCR doesn't rule out pneumonia—sensitivity decreases with prior antibiotic exposure and atypical pathogens.

MALDI-TOF Mass Spectrometry

Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS enables rapid organism identification directly from positive blood cultures or concentrated respiratory samples.

Advantages:

Species identification in 15-30 minutes
Cost-effective after initial setup
Expanding databases include resistance prediction algorithms¹³

Limitations:

Requires adequate organism load
Limited direct resistance detection
Cannot differentiate colonization from infection

Advanced Diagnostic Techniques

Next-Generation Sequencing (NGS)

Metagenomic NGS offers comprehensive pathogen identification and resistance gene detection.

Clinical Applications:

Unbiased pathogen detection
Outbreak investigation
Identification of novel resistance mechanisms¹⁴

Current Limitations:

Turnaround time: 24-48 hours
High cost
Bioinformatics expertise required
Interpretation challenges with commensal organisms

Biomarker-Guided Diagnosis

Procalcitonin:

Levels >0.5 ng/mL suggest bacterial infection
Useful for antibiotic de-escalation
Limited specificity in post-surgical patients¹⁵

Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1):

Emerging biomarker for bacterial pneumonia
May distinguish bacterial from viral pneumonia
Requires validation in larger cohorts¹⁶

💡 Clinical Hack: Combine biomarkers with clinical assessment—procalcitonin + CPIS score + chest imaging provides optimal diagnostic accuracy.

Antimicrobial Resistance Mechanisms

Understanding resistance mechanisms is crucial for selecting appropriate therapy and interpreting susceptibility results.

β-Lactamase-Mediated Resistance

Carbapenemases

Class A (KPC):

Predominant in K. pneumoniae
Hydrolizes most β-lactams including carbapenems
Inhibited by clavulanic acid and newer β-lactamase inhibitors¹⁷

Class B (Metallo-β-lactamases):

NDM, VIM, IMP variants
Hydrolyze all β-lactams except aztreonam
Not inhibited by conventional β-lactamase inhibitors¹⁸

Class D (OXA-type):

Common in A. baumannii (OXA-23, OXA-24, OXA-58)
Variable carbapenem hydrolysis
Challenging to detect phenotypically¹⁹

🦪 Oyster Alert: Carbapenem-susceptible, ceftazidime-resistant isolates may harbor undetected carbapenemases—consider combination testing.

Non-β-Lactamase Resistance

Efflux Pumps:

Multi-drug efflux systems in P. aeruginosa and A. baumannii
Confer resistance to multiple antibiotic classes
Target for novel inhibitors²⁰

Porin Mutations:

Outer membrane protein changes reduce antibiotic permeability
Common in carbapenem resistance
Often combined with β-lactamase production²¹

Novel Antimicrobial Agents

β-Lactam/β-Lactamase Inhibitor Combinations

Ceftazidime-Avibactam

Mechanism: Avibactam inhibits Class A, C, and some Class D β-lactamases

Spectrum:

Active against KPC-producing CRE
Excellent P. aeruginosa activity
Limited activity against metallo-β-lactamases²²

Clinical Evidence:

REPROVE trial: Non-inferiority to meropenem for cIAI
RECAPTURE trial: Superior to best available therapy for CRE infections²³

Dosing: 2.5g IV q8h (adjusted for renal function)

Resistance Concerns: Emerging resistance through blaKPC mutations and metallo-β-lactamase co-production²⁴

Meropenem-Vaborbactam

Mechanism: Vaborbactam inhibits Class A and C β-lactamases with minimal Class B activity

Spectrum:

Active against KPC and OXA-48 producers
Limited P. aeruginosa activity
No activity against metallo-β-lactamases²⁵

Clinical Evidence:

TANGO I: Superior to best available therapy for CRE UTI and cIAI
TANGO II: Non-inferiority to piperacillin-tazobactam for HAP/VAP²⁶

Dosing: 4g IV q8h

Imipenem-Cilastatin-Relebactam

Mechanism: Relebactam inhibits Class A and C β-lactamases

Spectrum:

Active against ESBL and some carbapenemase producers
Enhanced P. aeruginosa activity compared to imipenem alone²⁷

Clinical Evidence:

RESTORE-IMI 1: Non-inferiority to colistin + imipenem for imipenem-nonsusceptible bacterial infections
RESTORE-IMI 2: Non-inferiority to piperacillin-tazobactam for HAP/VAP²⁸

Dosing: 1.25g IV q6h

Novel β-Lactams

Cefiderocol

Mechanism: Siderophore cephalosporin that uses bacterial iron transport systems for uptake

Spectrum:

Broad activity against MDR gram-negative pathogens
Active against carbapenemases including metallo-β-lactamases
Some A. baumannii activity²⁹

Clinical Evidence:

APEKS-NP: Non-inferiority to meropenem for HAP/VAP
CREDIBLE-CR: Descriptive study in CRE infections with high mortality concerns³⁰

Dosing: 2g IV q8h (adjusted for renal function)

🦪 Oyster Alert: Iron-rich media can affect susceptibility testing—specialized testing conditions required for accurate MIC determination.

Anti-MRSA Agents

Ceftaroline

Mechanism: β-lactam with activity against MRSA through PBP2a binding

Clinical Evidence:

FOCUS trials: Non-inferiority to vancomycin for ABSSSI
ASPECT-NP: Non-inferiority to ceftazidime for HAP/VAP³¹

Dosing: 600mg IV q12h

Delafloxacin

Mechanism: Fluoroquinolone with enhanced activity against anaerobes and MRSA

Clinical Evidence:

Superior tissue penetration compared to levofloxacin
Non-inferiority to vancomycin + aztreonam for ABSSSI³²

Dosing: 300mg IV q12h

Treatment Strategies

Empirical Therapy Selection

🔍 Clinical Pearl: Implement risk-stratified empirical therapy protocols:

Low MDR Risk:

Piperacillin-tazobactam 4.5g IV q6h OR
Ceftriaxone 2g IV q24h + macrolide

Moderate MDR Risk:

Meropenem 2g IV q8h (extended infusion) OR
Cefepime 2g IV q8h + vancomycin 15-20mg/kg q12h

High MDR Risk:

Ceftazidime-avibactam 2.5g IV q8h + vancomycin OR
Meropenem-vaborbactam 4g IV q8h + linezolid

💡 Clinical Hack: Use "double coverage" for high-risk P. aeruginosa—combine β-lactam with fluoroquinolone or aminoglycoside until susceptibilities available.

Combination Therapy Considerations

Synergistic Combinations

For Carbapenem-Resistant A. baumannii:

Cefiderocol + colistin or minocycline
High-dose ampicillin-sulbactam + cefiderocol³³

For XDR P. aeruginosa:

Ceftolozane-tazobactam + amikacin
Ceftazidime-avibactam + aztreonam (for metallo-β-lactamase producers)³⁴

Duration of Combination Therapy

Evidence-Based Recommendations:

Continue combination for 48-72 hours minimum
De-escalate based on clinical response and susceptibilities
Avoid prolonged aminoglycoside use (>5-7 days)³⁵

Therapeutic Drug Monitoring

β-Lactam Optimization:

Target free drug concentrations >4× MIC for 100% dosing interval
Extended/continuous infusions for high MIC organisms
Adjust for altered pharmacokinetics in critically ill patients³⁶

Vancomycin Monitoring:

Target AUC₂₄/MIC ratio of 400-600
Avoid trough-based dosing
Monitor for nephrotoxicity with combination therapy³⁷

💡 Clinical Hack: For β-lactams, use extended infusions (3-4 hours) for organisms with MIC ≥4-8 mg/L to optimize pharmacodynamic targets.

Antimicrobial Stewardship

De-escalation Strategies

Biomarker-Guided De-escalation:

Procalcitonin decrease >80% by day 3-5 suggests appropriate therapy
Serial biomarker monitoring reduces antibiotic duration³⁸

Culture-Guided Adjustments:

Narrow spectrum once pathogen identified
Discontinue anti-MRSA therapy if MRSA not isolated after 48-72 hours
Switch to oral therapy when clinically appropriate³⁹

Novel Stewardship Approaches

Rapid Diagnostic Stewardship

Protocol Implementation:

Obtain respiratory samples before empirical therapy
Implement rapid diagnostics within 1-2 hours
Pharmacist-driven protocol adjustments based on results
Clinical reassessment at 24-48 hours⁴⁰

Artificial Intelligence Integration

Machine Learning Applications:

Predictive models for MDR risk stratification
Real-time antimicrobial optimization algorithms
Resistance pattern recognition and outbreak detection⁴¹

Special Populations and Scenarios

Immunocompromised Patients

Additional Considerations:

Extended spectrum of potential pathogens (fungi, viruses, atypical bacteria)
Higher risk for invasive fungal infections
Consider empirical antifungal therapy in high-risk patients⁴²

🔍 Clinical Pearl: In neutropenic patients with pneumonia, consider Stenotrophomonas maltophilia—use trimethoprim-sulfamethoxazole or tigecycline.

COVID-19 and Bacterial Coinfection

Epidemiological Changes:

Reduced overall HAP/VAP incidence during pandemic
Shift toward more resistant organisms
Increased A. baumannii and K. pneumoniae infections⁴³

Extracorporeal Support

ECMO-Associated Challenges:

Altered antibiotic pharmacokinetics
Increased infection risk
Consider therapeutic drug monitoring for all antibiotics⁴⁴

Prevention Strategies

VAP Prevention Bundles

Core Elements:

Head-of-bed elevation 30-45°
Daily sedation interruption and spontaneous breathing trials
Oral care with chlorhexidine
Subglottic suction endotracheal tubes⁴⁵

Emerging Interventions:

Selective oral decontamination (SOD) in specific settings
Early mobility protocols
Probiotic supplementation (investigational)⁴⁶

Environmental Control

Infection Prevention:

Contact isolation for MDR organisms
Enhanced environmental cleaning
Staff education and compliance monitoring⁴⁷

Future Directions

Pipeline Antibiotics

Cefepime-Taniborbactam

Mechanism: Novel β-lactamase inhibitor combination Spectrum: Broad gram-negative activity including CRE Development Status: Phase 3 trials ongoing⁴⁸

Aztreonam-Avibactam

Mechanism: Combination targeting metallo-β-lactamase producers Spectrum: Active against NDM, VIM, IMP producers Development Status: Phase 3 trials planned⁴⁹

Diagnostic Innovations

Point-of-Care Testing

Emerging Technologies:

Portable PCR platforms
Smartphone-based diagnostics
Breath analysis for pathogen detection⁵⁰

Artificial Intelligence Applications

Diagnostic Support:

Image analysis for chest X-ray interpretation
Clinical decision support systems
Predictive modeling for treatment response⁵¹

Practical Clinical Recommendations

🎯 Immediate Action Items for ICU Teams

Implement rapid diagnostic protocols
- Obtain respiratory samples before antibiotics
- Use multiplex PCR for high-risk patients
- Results available within 2-4 hours
Risk-stratify all pneumonia patients
- Use validated MDR risk factors
- Adjust empirical therapy accordingly
- Document rationale for antibiotic selection
Establish therapeutic drug monitoring
- β-lactam levels for high MIC organisms
- Vancomycin AUC monitoring
- Adjust for renal function and critical illness
Create de-escalation protocols
- 48-72 hour reassessment mandatory
- Biomarker-guided duration
- Pharmacist-driven adjustments

💊 Antibiotic Selection Pearls

For Suspected ESBL Producers:

First-line: Meropenem or piperacillin-tazobactam
Alternative: Ceftolozane-tazobactam

For Known/Suspected CRE:

KPC producers: Ceftazidime-avibactam or meropenem-vaborbactam
MBL producers: Cefiderocol ± aztreonam-avibactam (when available)
OXA-48: Ceftazidime-avibactam or cefiderocol

For XDR P. aeruginosa:

Ceftolozane-tazobactam + aminoglycoside
Consider cefiderocol for pan-resistant isolates

For CRAB:

Ampicillin-sulbactam (high-dose) + cefiderocol
Consider tigecycline or colistin combinations

🚨 Red Flag Situations

Rapid Clinical Deterioration:
- Consider resistant organisms or complications
- Broaden coverage immediately
- Obtain urgent imaging and cultures
Failure to Improve by 72 Hours:
- Reassess diagnosis and pathogen
- Check antibiotic levels
- Consider combination therapy
New Resistance During Therapy:
- Switch antibiotic classes
- Investigate transmission sources
- Implement contact precautions

Economic Considerations

Cost-Effectiveness Analysis

Rapid Diagnostics:

Initial high cost offset by reduced length of stay
Decreased inappropriate antibiotic use
Improved patient outcomes justify investment⁵²

Novel Antibiotics:

Higher acquisition costs
Potential to reduce resistance development
Need for pharmacoeconomic evaluation⁵³

Resource Optimization

Stewardship Program ROI:

Every $1 invested saves $3-7 in healthcare costs
Reduced antimicrobial resistance rates
Decreased adverse events and complications⁵⁴

Conclusions

The management of ICU-acquired pneumonia in the era of MDR pathogens requires a fundamental shift from traditional empirical approaches to precision medicine strategies. Rapid molecular diagnostics enable pathogen identification and resistance detection within hours rather than days, facilitating early appropriate therapy and improved outcomes.

The armamentarium of novel antibiotics, including ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol, provides new options for previously untreatable infections. However, judicious use guided by robust antimicrobial stewardship principles is essential to preserve their effectiveness.

Key success factors include:

Implementation of rapid diagnostic platforms
Risk-stratified empirical therapy protocols
Therapeutic drug monitoring for optimization
Systematic de-escalation strategies
Multidisciplinary stewardship programs

Future advances in artificial intelligence, point-of-care diagnostics, and novel antimicrobial mechanisms offer promise for further improving outcomes in this challenging patient population.

The battle against MDR pathogens in ICU-acquired pneumonia requires continuous adaptation of diagnostic and therapeutic strategies, supported by robust infection prevention measures and stewardship programs. Success depends on the integration of these elements into comprehensive, evidence-based clinical protocols.

References

Papazian L, et al. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46(5):888-906.
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655.
Kumar A, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596.
Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51 Suppl 1:S81-87.
CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019.
Pachori P, et al. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis. 2019;6(2):109-119.
Wong D, et al. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30(1):409-447.
Russo TA, et al. Hypervirulent K. pneumoniae: a call for new therapeutic strategies. J Clin Invest. 2018;128(12):5731-5741.
Rea-Neto A, et al. Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care. 2008;12(2):R56.
Schuetz P, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10(10):CD007498.
Buchan BW, et al. Evaluation of a novel multiplex high-definition PCR assay for detection of respiratory pathogens in nasopharyngeal specimens. J Clin Microbiol. 2020;58(7):e00608-20.
Gastli N, et al. Multicentric evaluation of BioFire FilmArray Pneumonia Panel for rapid bacterial detection in lower respiratory tract specimens. Clin Microbiol Infect. 2021;27(2):298.e1-298.e5.
Clark AE, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clin Microbiol Rev. 2013;26(3):547-603.
Charalampous T, et al. Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory tract infection. Nat Biotechnol. 2019;37(7):783-792.
Schuetz P, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-1066.
Gibot S, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004;350(5):451-458.
Munoz-Price LS, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785-796.
Walsh TR, et al. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18(2):306-325.
Evans BA, et al. OXA β-lactamases. Clin Microbiol Rev. 2014;27(2):241-263.
Blanco P, et al. Bacterial multidrug efflux pumps: much more than antibiotic resistance determinants. Microorganisms. 2016;4(1):14.
Masi M, et al. Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria. Nat Microbiol. 2017;2:17001.
Zhanel GG, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159-177.
Torres A, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285-295.
Shields RK, et al. Clinical evolution of AmpC-mediated ceftazidime-avibactam resistance in Enterobacter cloacae. J Infect Dis. 2017;215(12):1862-1868.
Wenzler E, et al. Meropenem-vaborbactam: a novel carbapenem-β-lactamase inhibitor combination agent for the treatment of multidrug-resistant gram-negative infections. Pharmacotherapy. 2018;38(4):444-455.
Wunderink RG, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439-455.
Haidar G, et al. Evaluating ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections: A review of the literature. Clin Infect Dis. 2017;64(9):1211-1222.
Motsch J, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799-1808.
Ito A, et al. Cefiderocol: A novel siderophore cephalosporin for the treatment of multidrug-resistant gram-negative bacteria. J Infect Chemother. 2018;24(7):490-496.
Bassetti M, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226-240.
File TM Jr, et al. Efficacy and safety of ceftaroline fosamil versus ceftriaxone in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 2011;66(6):1367-1373.
O'Riordan W, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018;67(5):657-666.
Karakonstantis S, et al. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to individual agents. Int J Antimicrob Agents. 2020;56(6):106085.
Tamma PD, et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169-e183.
Paul M, et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54(11):4851-4863.
Roberts JA, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498-509.
Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361-1364.
de Jong E, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819-827.
Barlam TF, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the

Tuesday, September 16, 2025